Airway Responses to Montelukast and Desloratadine.
Information source: University of Saskatchewan
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Montelukast (10mg) and Desloratadine (5mg) (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Saskatchewan Official(s) and/or principal investigator(s):
Donald W Cockcroft, MD, FRCP(C), Principal Investigator, Affiliation: University of Saskatchew Full Professor
Summary
Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their
current uses. Part of what happens when your allergies trigger your asthma should be
prevented by either of these drugs. This project is being conducted to determine if these
drugs are effective, either alone or in combination, on controlling asthma that is triggered
by allergies.
Clinical Details
Official title: Airway Responses to Montelukast and Desloratadine.
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Primary outcome: Late asthmatic response (maximum percent decrease in FEV1)
Secondary outcome: Early asthmatic response (maximum percent decrease in FEV1Changes in sputum cell/mediator content Changes in airway hyperresponsiveness (methacholine PC20)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- baseline FEV1 > or = 65% predicted
- positive methacholine challenge (i. e. methacholine PC20 < or = 16mg/ml
- positive allergen challenge
Exclusion Criteria:
- negative skin prick test
- lung condition/disease other than asthma
- currently use montelukast and/or desloratadine
Locations and Contacts
Room 346 Ellis Hall, Saskatoon, Saskatchewan S7N 0W8, Canada
Additional Information
Starting date: January 2007
Ending date: August 2007
Last updated: January 18, 2008
|
